CTI BioPharma (CTIC) Stock Forecast, Price & News

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CTI BioPharma in the last twelve months. There are currently 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CTIC shares.
View CTIC analyst ratings or view top-rated stocks.

10 analysts have issued 1-year price objectives for CTI BioPharma's stock. Their CTIC share price forecasts range from $8.00 to $13.00. On average, they expect the company's share price to reach $10.29 in the next year. This suggests a possible upside of 13.8% from the stock's current price.
View analysts price targets for CTIC or view top-rated stocks among Wall Street analysts.

CTI BioPharma's stock was trading at $6.01 at the start of the year. Since then, CTIC stock has increased by 50.4% and is now trading at $9.04.
View the best growth stocks for 2023 here.

CTI BioPharma saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 8,080,000 shares, a decline of 33.6% from the April 30th total of 12,170,000 shares. Based on an average daily trading volume, of 5,760,000 shares, the days-to-cover ratio is currently 1.4 days.
View CTI BioPharma's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our CTIC earnings forecast.

CTI BioPharma Corp. (NASDAQ:CTIC) posted its earnings results on Monday, March, 6th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.04. The biopharmaceutical company had revenue of $21.08 million for the quarter, compared to analysts' expectations of $24.88 million. During the same period in the prior year, the business earned ($0.38) earnings per share.

ETFs with the largest weight of CTI BioPharma (NASDAQ:CTIC) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Future Gen 200 ETF (QQQS), Principal Healthcare Innovators ETF (BTEC), Vanguard U.S. Momentum Factor ETF (VFMO),

CTI BioPharma's stock reverse split before market open on Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 30th 2016. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

8 employees have rated CTI BioPharma Chief Executive Officer James A. Bianco on Glassdoor.com. James A. Bianco has an approval rating of 27% among the company's employees. This puts James A. Bianco in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other CTI BioPharma investors own include Edap Tms (EDAP), Energous (WATT), Adverum Biotechnologies (ADVM), Weatherford International (WFT), XOMA (XOMA), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Vaxart (VXRT), Dynavax Technologies (DVAX) and Trevena (TRVN).

CTI BioPharma trades on the NASDAQ under the ticker symbol "CTIC."

CTI BioPharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include State Street Corp (9.43%), Rubric Capital Management LP (6.80%), BlackRock Inc. (5.39%), Stonepine Capital Management LLC (4.96%), Bain Capital Life Sciences Investors LLC (3.57%) and Bank of America Corp DE (2.66%). Insiders that own company stock include Adam R Craig, Bvf Partners L P/Il, David Kirske, James K Fong, Michael A Metzger and Orbimed Advisors Llc.
View institutional ownership trends.

Shares of CTIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CTIC stock can currently be purchased for approximately $9.04.

CTI BioPharma (NASDAQ:CTIC) has a market capitalization of $1.19 billion and generates $53 million in revenue each year. The biopharmaceutical company earns $-92,990,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis.

CTI BioPharma's mailing address is 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121. The official website for the company is www.ctibiopharma.com. The biopharmaceutical company can be reached via phone at (206) 282-7100, via email at invest@ctibiopharma.com, or via fax at 206-284-6206.